Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. - Wikidata - awgldk - TriplyDB

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

http://www.wikidata.org/entity/Q36874767

about

Modern Radiotherapy Concepts and the Impact of Radiation on Immune Activation Therapeutic vaccines as a promising treatment modality against prostate cancer: rationale and recent advances The interplay of immunotherapy and chemotherapy: harnessing potential synergies Tumor Cells Surviving Exposure to Proton or Photon Radiation Share a Common Immunogenic Modulation Signature, Rendering Them More Sensitive to T Cell-Mediated Killing Immunotherapy and therapeutic vaccines in prostate cancer: an update on current strategies and clinical implications The immunocytokine NHS-IL12 as a potential cancer therapeutic Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment A pan inhibitor of DASH family enzymes induces immunogenic modulation and sensitizes murine and human carcinoma cells to antigen-specific cytotoxic T lymphocyte killing: implications for combination therapy with cancer vaccines.Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway Exploiting synergy: immune-based combinations in the treatment of prostate cancer.(R)Evolutionary therapy: the potential of immunotherapy to fulfill the promise of personalized cancer treatment Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.Immune cell-based screening assay for response to anticancer agents: applications in pharmacogenomics.Combinatorial strategies for the induction of immunogenic cell death.Adding fuel to the fire: immunogenic intensification.Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade.Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death.Inhibitors of histone deacetylase 1 reverse the immune evasion phenotype to enhance T-cell mediated lysis of prostate and breast carcinoma cells.Histomorphological Factors Predicting the Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.Immunogenic cell death due to a new photodynamic therapy (PDT) with glycoconjugated chlorin (G-chlorin).Anti-tumor immunity of BAM-SiPc-mediated vascular photodynamic therapy in a BALB/c mouse model.Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing.Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.Amplification of MUC1 in prostate cancer metastasis and CRPC development TLR4 is essential for dendritic cell activation and anti-tumor T-cell response enhancement by DAMPs released from chemically stressed cancer cells.Preclinical vaccines against mammary carcinoma.Immature, Semi-Mature, and Fully Mature Dendritic Cells: Toward a DC-Cancer Cells Interface That Augments Anticancer Immunity Prostate cancer vaccines: the long road to clinical application.A Pilot Study of Stereotactic Body Radiation Therapy Combined with Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.Integrating Immunotherapies in Prostate Cancer.Cancer Vaccines: Enhanced Immunogenic Modulation through Therapeutic Combinations.CAR T-cell immunotherapy: The path from the by-road to the freeway?Immunotherapy of Prostate Cancer: Facts and Hopes.Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?Calreticulin, a therapeutic target?

P2860

Q26744490-D6A16517-2E70-48AC-8C46-D1AB435F6495 Q26827475-EA05D575-EF0F-4A68-942C-004B654E89A5 Q28081893-9E77ED17-99CC-419B-B9CC-5D2EE234912C Q33275987-795A84F2-D948-40F9-9A88-EC7250068FA5 Q33621393-3AA71A71-B8BA-4000-8E9C-3F5F29AC391B Q33688398-875C56B5-376F-4AD1-8AB2-3BC9C76D714D Q33718182-F64A42F5-EF67-4BE0-B917-18315F75117D Q33760877-22385CA6-6AC5-4809-83EA-2EB0E82B13C9 Q33930599-ACDBA727-A205-4683-BD7D-75E0D16E765F Q34444867-4230AEDD-C33D-4936-98C0-00B8B08C612B Q34687216-2716C69B-1DDF-4751-A57C-5B4176D9C156 Q34736597-36698DA1-2BA4-4A68-8BE2-F4B3F5368D2C Q34876404-F19F6951-9CC8-4FB5-BED1-43F2948CF441 Q35425222-ABDCBECF-8181-4C51-BF11-4CAB3E2E5168 Q35535140-4E88D4C7-1D17-4ABE-804E-3E8A15CE3A34 Q35886393-535DACD6-2420-45C1-B419-624F419B29BD Q35922726-C3FF8743-71FA-4E66-B3B7-ACEDCCFB548F Q36228550-C535EF0B-CB79-4975-A9A6-F7BA04FADFA8 Q36286833-1F773EA1-634B-4050-AD34-500369A36796 Q36301061-A01CF49C-FAD1-4619-9441-D16A33E2AEE6 Q36946516-A3DD06C1-3CC5-4F7D-A5EF-BF31933FBBBD Q37316603-2C84F639-3DE6-4572-9BF7-20BB4C23288B Q37324881-36F009AD-6098-44E9-B968-AD25D563645C Q37515914-5ADF4F6E-43F4-44B8-A28F-05EC780D2BCF Q37565103-350C7D63-8117-4C2D-A8E1-1ADEE9F8FAC8 Q37634941-76752F03-5095-4C4A-B201-BB8D3D94C4EA Q37660302-64EF4F4F-E3DF-457A-A294-67EFE9908C4A Q37686296-06EA76BF-2CB0-4711-B59A-CC7560EA33FD Q37696276-064E6481-1DF1-41C1-8723-AB5E0060E1BE Q37729984-5DA1144E-AE39-4657-87E2-F0307DF83BD0 Q38160252-59F0BC4F-F44D-45C7-8154-EA436AF75106 Q38174601-D6BC4D8D-B6EA-4A02-AB9A-1EBA0A8D9959 Q38359237-EE8302C8-57C3-4F60-943F-C8405EEF5517 Q38373731-6D4D9A5D-1B78-44AD-9917-3E4BA2951EE6 Q38567067-A6A70C1C-9AB8-4992-9769-ABC529A4C6EC Q38600417-17E16CC3-96B9-4B4D-83C8-F5A9D2D2C069 Q38632105-BB39C840-4F0F-4CDF-A917-B9D29BC2759F Q38664882-4622F921-5702-4595-9B0D-3793201A0E0A Q38763935-E2D95156-FAE7-4E60-9BE3-99E5FB650063 Q38766974-D8E95286-F9BA-4A5C-B693-D032391E8995

P2860

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

http://www.wikidata.org/entity/Q36874767

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Chemotherapy-induced immunogen ...... t from immunogenic cell death.

@en

type

label

Chemotherapy-induced immunogen ...... t from immunogenic cell death.

@en

prefLabel

Chemotherapy-induced immunogen ...... t from immunogenic cell death.

@en

P1433

Q36874767-943BA90A-BF6F-4AFC-9B76-2272BBADC65C

P1476

Q36874767-745244A2-7D37-4480-94EB-85A06B97BB1F

P2093

Q36874767-28146823-D40F-49AF-8A0C-63A83E5AF83D

Q36874767-6B289C7E-0A32-4BAD-A3C9-728692AEDAC2

Q36874767-6F7DC72D-8644-4D2B-A57F-64F01C8ECABA

Q36874767-77A92433-5BC2-4D9D-9A09-BE5F1FDD421C

P2860

Q36874767-064AF7C2-4121-4518-95DC-72DB05BE9166

Q36874767-0F15A10F-CA2B-40FE-A02F-C3D0F6BA22B0

Q36874767-111C6545-A14F-4F4E-AB00-E025DF599D6B

Q36874767-1D17E0EF-4F9D-445E-A5A0-FF48D8A7402C

Q36874767-280DBA28-9B79-441C-BC43-EDAB94F12CB5

Q36874767-28686B18-F6FD-4098-8173-00458805C7BE

Q36874767-2A435DA2-3243-4511-9B08-C72A54305B6E

Q36874767-2DF309BB-F55C-44E1-AF95-2CB6022395AA

Q36874767-2F9000D9-957F-4420-9079-5A384E349ECA

Q36874767-30310D49-B379-4969-A71F-CADAABEE7859

P304

Q36874767-9FD407AC-5BA4-4440-A429-11E89F2D930A

P31

Q36874767-176D28EA-B30C-4154-85CF-24B20D61F7EB

P356

Q36874767-4903CF1D-88B9-4B7E-ACF3-F00456DE55C8

P433

Q36874767-E37C9933-2EED-4BC0-9F20-1366875F464C

P478

Q36874767-D843DD12-212B-47D1-AA4F-23918570E791

P50

Q36874767-CD6A1C81-7B86-42AB-A691-48BF6E50B90B

Q36874767-CE28EFF0-7324-4FC2-AC0E-03F0A42D05F1

Q36874767-D3E4ED32-9B02-4D55-BDD4-D371341FBBE9

P577

Q36874767-42872CBE-A23D-40D5-9F69-0A36471EAC45

P5875

Q36874767-1EA09437-8C76-44BE-86EE-16ABB1C97F76

P698

Q36874767-33DEF321-81C3-4FA7-B0AF-267232229491

P921

Q36874767-44D155EE-62DF-43FD-B354-4B9AC200B9B0

Q36874767-4632DB8C-9384-4308-8EDD-756DF25FF51F

P932

Q36874767-A1FCA09E-FBF8-4628-AD57-5E66F9B72AF5

P356

P1433

International Journal of Cancer

P1476

Chemotherapy-induced immunogen ...... ct from immunogenic cell death

@en

P2093

Claudia Palena

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

Kwong-Yok Tsang

http://www.w3.org/2001/XMLSchema#string

Soldano Ferrone

http://www.w3.org/2001/XMLSchema#string

P2860

Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death

A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer

Reduced expression of p27 is a novel mechanism of docetaxel resistance in breast cancer cells

Alterations in the antigen processing-presenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma

Drug resistance in cancer: principles of emergence and prevention.

On the definition of a criterion of immunogenicity.

The immunological effects of taxanes.

Antigen-processing machinery breakdown and tumor growth.

P304

624-636

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/IJC.28070

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

133

http://www.w3.org/2001/XMLSchema#string

P50

Benedetto Farsaci

Sofia R Gameiro

Charlie Garnett-Benson

P577

2013-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235386065

http://www.w3.org/2001/XMLSchema#string

P698

23364915

http://www.w3.org/2001/XMLSchema#string

P921

P932

3663913

http://www.w3.org/2001/XMLSchema#string